Wenjia Liang

Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

DSN1 may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy.

DSN1 may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy.

Journal: Cancer biology & therapy

Published: November 18, 2024

High expression of ARPC1B promotes the proliferation and apoptosis of clear cell renal cell carcinoma cells, leading to a poor prognosis.

High expression of ARPC1B promotes the proliferation and apoptosis of clear cell renal cell carcinoma cells, leading to a poor prognosis.

Journal: Molecular and cellular probes

Published: November 10, 2023

Clinical Outcomes After Cranioplasty With Titanium Mesh, Polyetheretherketone, or Composite Bone Cement: A Retrospective Study.

Clinical Outcomes After Cranioplasty With Titanium Mesh, Polyetheretherketone, or Composite Bone Cement: A Retrospective Study.

Journal: The Journal of craniofacial surgery

Published: February 07, 2023

Post-traumatic brain injury glioma: Characteristics, report of 2 cases report and literature review.

Post-traumatic brain injury glioma: Characteristics, report of 2 cases report and literature review.

Journal: Medicine

Published: January 03, 2023

PSRC1 Regulated by DNA Methylation Is a Novel Target for LGG Immunotherapy.

PSRC1 Regulated by DNA Methylation Is a Novel Target for LGG Immunotherapy.

Journal: Journal of molecular neuroscience : MN

Published: December 15, 2022

ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.

ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.

Journal: The international journal of biochemistry & cell biology

Published: November 12, 2022

WD repeat domain 76 predicts poor prognosis in lower grade glioma and provides an original target for immunotherapy.

WD repeat domain 76 predicts poor prognosis in lower grade glioma and provides an original target for immunotherapy.

Journal: European journal of medical research

Published: October 15, 2022

ZNF480 influences the prognosis, pathogenesis, and immune microenvironment in patients with lower-grade glioma.

ZNF480 influences the prognosis, pathogenesis, and immune microenvironment in patients with lower-grade glioma.

Journal: Heliyon

Published: August 21, 2022

Exploring the relationship between abnormally high expression of NUP205 and the clinicopathological characteristics, immune microenvironment, and prognostic value of lower-grade glioma.

Exploring the relationship between abnormally high expression of NUP205 and the clinicopathological characteristics, immune microenvironment, and prognostic value of lower-grade glioma.

Journal: Frontiers in oncology

Published: August 02, 2022

Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.

Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.

Journal: International immunopharmacology

Published: July 14, 2021

Prognostic Significance of mRNA Expression RBBP8 or Its Methylation in Gliomas.

Prognostic Significance of mRNA Expression RBBP8 or Its Methylation in Gliomas.

Journal: Cellular and molecular neurobiology

Published: July 12, 2021

CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.

CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.

Journal: Current research in translational medicine

Published: June 30, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026